<code id='6C2394086F'></code><style id='6C2394086F'></style>
    • <acronym id='6C2394086F'></acronym>
      <center id='6C2394086F'><center id='6C2394086F'><tfoot id='6C2394086F'></tfoot></center><abbr id='6C2394086F'><dir id='6C2394086F'><tfoot id='6C2394086F'></tfoot><noframes id='6C2394086F'>

    • <optgroup id='6C2394086F'><strike id='6C2394086F'><sup id='6C2394086F'></sup></strike><code id='6C2394086F'></code></optgroup>
        1. <b id='6C2394086F'><label id='6C2394086F'><select id='6C2394086F'><dt id='6C2394086F'><span id='6C2394086F'></span></dt></select></label></b><u id='6C2394086F'></u>
          <i id='6C2394086F'><strike id='6C2394086F'><tt id='6C2394086F'><pre id='6C2394086F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:4357
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Brain injuries and the importance of a second opinion
          Brain injuries and the importance of a second opinion

          Photoillustration:CaseySheneryforSTATHowoldisClaireSnyman?“Iamnow…”shesayswithpause.“Ialwayshavetoth

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

          HasPhRMAlostitsfangs?Are11th-hourchangesominousforclinicaltrials?Andwhat’snextinpainmedicine?Wecover